Synergism of H2 histamine receptor antagonists with alpha-interferon to inhibit the growth of leukemic and normal hematopoietic progenitors.
Douer
D
D
Institute of Hematology, Chaim Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel-Aviv University Israel.
Ben-Bassat
I
I
Kneller
A
A
Chitayat
S D
SD
Shaked
N
N
Salzberg
S
S
Ramot
B
B
D002455:Cell Division / Q000187:drug effects; D002927:Cimetidine / Q000494:pharmacology; D003864:Depression, Chemical; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured / Q000187:drug effects
D006635:Histamine H2 Antagonists; D007370:Interferon Type I; D011994:Recombinant Proteins; D002927:Cimetidine